Rezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Wedbush Analyst Says

Rezolute (NASDAQ:RZLT – Get Free Report) had its price target increased by research analysts at Wedbush from $6.00 to $10.00 in a research note issued on Tuesday, Marketbeat reports. The firm presently has an “outperform” rating on the stock. Wedbush‘s price target would suggest a potential upside of 135.29% from the stock’s current price.

RZLT has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a research report on Thursday, October 15th. Zacks Research downgraded Rezolute from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Citizens Jmp boosted their target price on shares of Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, October 6th. Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a research report on Monday, October 5th. Finally, Lake Street Capital upped their price target on shares of Rezolute from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Rezolute has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Get Our Latest Report on RZLT

Rezolute Trading Up 6.0%

Shares of NASDAQ RZLT opened at $4.25 on Tuesday. The firm has a market cap of $411.10 million, a P/E ratio of -5.59 and a beta of 0.65. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.16. The business’s 50 day moving average is $4.05 and its 200-day moving average is $3.93.

Rezolute (NASDAQ:RZLT – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. Analysts forecast that Rezolute will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jennison Associates LLC acquired a new stake in shares of Rezolute in the 1st quarter valued at $10,489,000. Siren L.L.C. bought a new position in shares of Rezolute in the 1st quarter valued at $10,151,000. Blue Owl Capital Holdings LP acquired a new position in shares of Rezolute during the 3rd quarter worth $3,871,000. Dimensional Fund Advisors LP raised its holdings in shares of Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock worth $1,617,000 after buying an additional 388,346 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Rezolute during the 3rd quarter worth $899,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.